Showing results (1231-1240 of 1,650) with videos related to
Sort By:
Pageof 165
Therapeutic Innovation & Regulatory Science|December 8, 2018
Potential Use of Artificial Intelligence for Regulatory Intelligence: Biopharmaceutical Industry's ViewsMark Mayer, Angelica Canedo, Tam Dinh, et al.Therapeutic Innovation & Regulatory Science|May 18, 2023
Validation of Artificial Intelligence Containing Products Across the Regulated Healthcare IndustriesDavid C Higgins, Christian JohnerTherapeutic Innovation & Regulatory Science|September 21, 2018
Adaptive Design Practice at the Center for Devices and Radiological Health (CDRH), January 2007 to May 2013Xiting Yang, Laura Thompson, Jianxiong Chu, et al.Therapeutic Innovation & Regulatory Science|July 11, 2026
Association Between FDA Drug Recall Classification and Product-Related CharacteristicsLantider K Bekele, M Affan Badar, Christopher J KluseTherapeutic Innovation & Regulatory Science|March 28, 2026
Ethical and Regulatory Awareness of Clinical Trials: A Nationwide Cross-Sectional Study from PolandDamian Swieczkowski, Jacek Burzyński, Aleksander Kwaśny, et al.Therapeutic Innovation & Regulatory Science|March 26, 2026
RWE Submission for European Regulators and Payers: Challenges, Uncertainties, and OpportunitiesLockwood Taylor, Blythe AdamsonTherapeutic Innovation & Regulatory Science|March 19, 2026
Parents' Perspectives on Access to Pediatric Rare Disease Cross-Border Clinical Trials in Europe: Experiences of Language Inclusion and PreferencesBegonya Nafria, Segolene Gaillard, Martine Dehlinger-Kremer, et al.Therapeutic Innovation & Regulatory Science|April 25, 2026
Clinicians' Reactions to Point-of-Care Advertising in Electronic Health RecordsBethany L Tennant, Teresa Koenig, Sarah Bennett-Harper, et al.Therapeutic Innovation & Regulatory Science|April 25, 2026
Why MASLD Trials Underselect the MENA Region Sites and What Sponsors and Regulators Must ChangeMohamed El-Kassas, Khalid M AlNaamani, Khalid Alswat, et al.Therapeutic Innovation & Regulatory Science|April 24, 2026
Present and Future Post-marketing Drug Safety Assessment in Japan: A PMDA PerspectiveTakashi Waki, Shinya Watanabe, Takashi Ando, et al.Pageof 165